PMV Pharmaceuticals announces promising data from Phase 2 rezatapopt trial
PMVP•PMV Pharmaceuticals reported a 48% confirmed response rate and 10.4-month median duration in its ovarian cancer cohort. The company plans to submit a rezatapopt NDA for ovarian cancer in the first quarter of 2027.
1. Trial results
PMV Pharmaceuticals reported a 48% confirmed overall response rate and a 10.4-month median duration in the ovarian cancer cohort of its Phase 2 Pynnacle trial. Across all cohorts, the overall response rate was 36%, with a median duration of 8.1 months. Eleven patients discontinued treatment because of adverse events.
2. Planned filing
The company plans to submit a rezatapopt NDA for ovarian cancer in the first quarter of 2027.




